Literature DB >> 17059472

Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration.

H Kojima1, M Moroi, S M Jung, S Goto, N Tamura, Y Kozuma, K Suzukawa, T Nagasawa.   

Abstract

BACKGROUND: There have been only seven reported cases of glycoprotein (GP) VI deficiency. However, the pathogenesis of this disorder has not been well-elucidated.
OBJECTIVES: We characterized a novel patient with GPVI deficiency and used these platelets to investigate the role of GPVI in normal hemostasis. PATIENT: A 31-year-old female with immune thrombocytopenic purpura who had been suffering from mild bleeding diathesis even after recovery from thrombocytopenia. RESULTS AND
CONCLUSION: The patient's platelets did not aggregate in response to either convulxin or collagen-related peptide. Immunoblotting revealed complete absence of the GPVI molecule, whereas a significantly reduced but substantial amount of Fc receptor (FcR) gamma-chain was expressed. Platelet stimulation with convulxin did not induce tyrosine-phosphorylation of FcR gamma-chain, indicating a defect in GPVI-mediated signaling. Concerning the underlying pathogenesis, we found normal level of GPVI-mRNA expression, no aberration of the sequence of the entire coding region of GPVI, and presence of degraded GPVI in her plasma. However, no anti-GPVI autoantibody was detected either by the binding assay to GPVI-Fc2 fusion protein or by immunoblotting/immunoprecipitation using the patient's immunoglobulin. We thus consider that either a short-time exposure to anti-GPVI autoantibody or a continuous exposure to low titers of the autoantibody has resulted in persistent GPVI deficiency. Under high shear flow, the patient's platelets could not form large aggregates, although initial platelet attachment was obviously observed. These results suggest that GPVI deficiency in this patient resulted in defective platelet thrombi development, manifesting as bleeding diathesis. Furthermore, our observations indicate that coordination of GPVI with integrin alpha2beta1 is essential for physiological platelet thrombus formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059472     DOI: 10.1111/j.1538-7836.2006.02173.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  3 in total

1.  GSK3beta is a negative regulator of platelet function and thrombosis.

Authors:  Dongjun Li; Shelley August; Donna S Woulfe
Journal:  Blood       Date:  2008-01-24       Impact factor: 22.113

2.  Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.

Authors:  Alexander P Bye; Amanda J Unsworth; Michael J Desborough; Catherine A T Hildyard; Niamh Appleby; David Bruce; Neline Kriek; Sophie H Nock; Tanya Sage; Craig E Hughes; Jonathan M Gibbins
Journal:  Blood Adv       Date:  2017-12-12

3.  The Small GTPase Rap1b: A Bidirectional Regulator of Platelet Adhesion Receptors.

Authors:  Gianni Francesco Guidetti; Mauro Torti
Journal:  J Signal Transduct       Date:  2012-06-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.